The fungal cell wall as a target for the development of new antifungal therapies
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
In the past three decades invasive mycoses have globally emerged as a persistent source of healthcare-associated infections. The cell wall surrounding the fungal cell opposes the turgor pressure that otherwise could produce cell lysis. Thus, the cell wall is essential for maintaining fungal cell shape and integrity. Given that this structure is absent in host mammalian cells, it stands as an important target when developing selective compounds for the treatment of fungal infections. Consequently, treatment with echinocandins, a family of antifungal agents that specifically inhibits the biosynthesis of cell wall (1-3)β-D-glucan, has been established as an alternative and effective antifungal therapy. However, the existence of many pathogenic fungi resistant to single or multiple antifungal families, together with the limited arsenal of available antifungal compounds, critically affects the effectiveness of treatments against these life-threatening infections. Thus, new antifungal therapies are required. Here we review the fungal cell wall and its relevance in biotechnology as a target for the development of new antifungal compounds, disclosing the most promising cell wall inhibitors that are currently in experimental or clinical development for the treatment of some invasive mycoses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
The Fungal Cell Wall: Structure, Biosynthesis, and Function
Gow, N. A. R., Latge, J.-P., & Munro, C. A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0035-2016 · Cited by 1,423
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
The cell wall: a carbohydrate armour for the fungal cell
Latgé, J. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05872.x · Cited by 987
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
Cell Wall Assembly in Saccharomyces cerevisiae
Lesage, G., & Bussey, H. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00038-05 · Cited by 849
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
Cited by
The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species
Garcia-Rubio, R., de Oliveira, H. C., Rivera, J., & Trevijano-Contador, N. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02993 · Cited by 917
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
“The fungal cell wall has a different structure in relation to human cells and this unique structure is an appealing target for the development of antifungal drugs [132].”
BackgroundSpecificity Influences in (1→3)-β-d-Glucan-Supported Diagnosis of Invasive Fungal Disease
Finkelman, M. A. (2020) · Journal of Fungi · doi:10.3390/jof7010014 · Cited by 76
“It is not produced in mammals, nor are mammals capable of its enzymatic degradation [22].”
BackgroundYang, G., Niu, X., Zhuang, T., Zhu, X., Xu, Q., Wang, H., Shao, J., Wang, C., Yang, Y., Wang, T., et al. (2025) · Virulence · doi:10.1080/21505594.2025.2519149 · Cited by 4
“The cell wall constitutes a highly dynamic structure, and its disruption exerts a profound impact on the survival of fungal cells, culminating in plasma membrane rupture and subsequent cell lysis [23].”
Metadata
- Authors
- Cortés, J. C. G., Curto, M.-Á., Carvalho, V. S. D., Pérez, P., & Ribas, J. C.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 37
- Issue
- 6
- Pages
- 107352
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W2917402352
- Cited by
- 170
- References
- 67
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.